NCT06714006 - Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

DRUG

PYC-003

A peptide-phosphorodiamidate morpholino oligonucleotide conjugate administered as a single intravenous infusion

Trial Locations (6)

RECRUITING

Westmead Hospital, Clinical Research Unit, Level 6, B Wing/Building, Hawkesbury Road, Westmead

RECRUITING

Liverpool Hospital, Clinic G-Reception 133, Level 1, Clinical Building, Burnside Drive, Liverpool

NOT_YET_RECRUITING

Doherty Clinical Trials (Satellite site for Sunshine Hospital), Level 2, 2 St Andrews Place, East Melbourne

RECRUITING

Mater Hospital Brisbane, South Brisbane

RECRUITING

South Coast Renal, Brockway House, Level 1, Suite 8, 82-86 Queen Street,, Southport

RECRUITING

Linear Clinical Research, Joondalup